Pharvaris Revenue and Competitors
Estimated Revenue & Valuation
- Pharvaris's estimated annual revenue is currently $10.5M per year.
- Pharvaris's estimated revenue per employee is $92,496
- Pharvaris's current valuation is $595.7M. (January 2022)
Employee Data
- Pharvaris has 113 Employees.
- Pharvaris grew their employee count by 20% last year.
Pharvaris's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder & CEO | Reveal Email/Phone |
2 | Head Global Program Management, VP | Reveal Email/Phone |
3 | VP, Head Biometrics & Data Science | Reveal Email/Phone |
4 | VP, Head Clinical Development Operations | Reveal Email/Phone |
5 | Head Data Management, Data Standard, and Programming | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Director, Clinical Quality | Reveal Email/Phone |
8 | Director, Clinical Data Management | Reveal Email/Phone |
9 | Chief Legal Officer and Board Secretary | Reveal Email/Phone |
10 | Chief Business Officer | Reveal Email/Phone |
Pharvaris Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Pharvaris?
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
keywords:N/A
N/A
Total Funding
113
Number of Employees
$10.5M
Revenue (est)
20%
Employee Growth %
$595.7M
Valuation
N/A
Accelerator
Pharvaris News
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel,...
Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights · Phase 1 pharmacokinetics study...
Data demonstrate PHA121 to be a potent human bradykinin B2 receptor antagonist. March 22, 2022 08:10 ET | Source: Pharvaris N.V. Pharvaris N.V..
Other Companies in Zug
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.4M | 116 | 14% | N/A |
#2 | $25.5M | 116 | 5% | N/A |
#3 | $30.5M | 120 | 28% | N/A |
#4 | $24.4M | 121 | 19% | N/A |
#5 | $16M | 123 | 4% | N/A |